Acacia Research Corporation — Q2 2014 Form 10-Q
Reporting period: Three and six months ended June 30, 2014. Acacia’s subsidiaries acquire or partner for patent rights, then license and enforce those rights. The interim financial statements are unaudited.
Financial results and liquidity
| Metric | Q2 2014 | Six months 2014 |
|---|---|---|
| Revenue | $50.1 million | $62.7 million |
| Operating loss | $8.2 million | $34.3 million |
| Net loss attributable to Acacia | $12.9 million | $37.4 million |
| Basic and diluted loss per share | $0.27 | $0.78 |
| Operating cash flow | Not separately stated for the quarter | $(0.6) million |
At June 30, cash and cash equivalents were $146.0 million and short-term investments were $74.8 million, totaling $220.8 million. Working capital was $211.9 million. The company reported no long-term debt or credit lines; contractual obligations were $14.9 million, including $6.0 million in scheduled patent-acquisition payments. Management said available resources and anticipated operating cash flows should cover requirements through at least August 2015.
Six-month investing cash flow was positive $33.2 million, including net proceeds from investment maturities and sales, offset in part by $22.1 million invested in patents. Financing cash outflow was $13.2 million, including $12.5 million of dividends paid.
Changes versus comparable periods
- Q2 revenue rose 117% year over year to $50.1 million, while the six-month total fell 37% to $62.7 million. Management attributed the half-year decline primarily to fewer agreements executed.
- Q2 operating loss narrowed to $8.2 million from $22.9 million a year earlier; six-month operating loss widened to $34.3 million from $15.8 million.
- Q2 revenue increased despite fewer agreements: 15 versus 43, with average revenue per agreement of $3.338 million versus $537,000. For the half year, agreements were 35 versus 72.
- Patent amortization rose 23% in both comparison periods, to $15.5 million for Q2 and $30.0 million for six months. Six-month amortization included a $2.6 million partial portfolio write-down and accelerated amortization associated with portfolio sales or terminations.
- Six-month accounts receivable increased to $25.2 million from $6.3 million at year-end; royalties and contingent legal fees payable rose to $20.3 million from $10.4 million. The company said most receivables were collected or scheduled for collection in Q3, with most related payables expected in Q3 or Q4.
Outlook, risks and unusual items
- Management described a strategic shift toward fewer, higher-quality patent portfolios and customers, while pursuing international licensing opportunities and additional portfolio partnerships. No revenue or earnings guidance was provided.
- Revenue is volatile and depends on agreement timing, licensing-program maturity, negotiations and litigation. Customer concentration was substantial: two licensees generated 72% of Q2 revenue and 57% of six-month revenue.
- Patent-related litigation and licensing costs may fluctuate and could rise with trials, international enforcement and portfolio prosecution. The filing also notes potential adverse court rulings, sanctions, fee awards and legislative or regulatory changes affecting patent enforcement.
- A California insurance-fraud-prevention lawsuit was in trial and expected to continue into August 2014. Acacia said it believed the claims lacked merit and did not expect a material adverse financial effect, but provided no assurance of success.
- Income tax expense included foreign withholding taxes and valuation allowances against certain tax assets. The effective tax rates were 56% for Q2 and 10% for the six-month period; these tax effects contributed to the reported net losses.
- The board approved a $0.125-per-share quarterly dividend payable in August 2014. Future dividends remain at the board’s discretion.
Important facts for investors to verify
- Whether the unusually high Q2 average revenue per agreement and revenue concentration are repeatable; compare subsequent agreements and collections.
- Progress on portfolio monetization, litigation timelines and legal expenses, including the Strathmann case and risks of sanctions or adverse rulings.
- Receivable collection and settlement of royalty and contingent legal-fee liabilities, and the effect of patent investments and amortization on cash generation.
- Future tax expense and any changes in valuation allowances or realizability of tax assets.
- Whether operating cash flow improves and whether dividends remain supportable given revenue volatility and patent investment needs.